Tumor-resident microbiota in breast cancer promotes both the initiation and progression of cancer. However, the potential of targeting microbiota to enhance the efficacy of breast cancer treatment has not been comprehensively explored. In this study, researchers analyzed the microbial composition within breast tumors and identified a notable enrichment of ETBF in patients who exhibited resistance to taxane-based neoadjuvant chemotherapy.
Key findings from the study include:
These findings suggest that inhibiting the NOD1 pathway and eliminating ETBF from the tumor microenvironment could potentially sensitize breast cancer cells to chemotherapy by impairing BCSCs. These results highlight the importance of considering the microbiome as a factor in cancer treatment and represent a promising avenue for developing novel therapeutic strategies aimed at enhancing the efficacy of existing breast cancer treatments. The work entitled “ Microbiota enterotoxigenic Bacteroides fragilis-secreted BFT-1 promotes breast cancer cell stemness and chemoresistance through its functional receptor NOD1 ” was published on Protein & Cell (published on Mar 4, 2024).
Protein & Cell
Experimental study
Animals
Microbiota enterotoxigenic Bacteroides fragilis-secreted BFT-1 promotes breast cancer cell stemness and chemoresistance through its functional receptor NOD1
4-Mar-2024